11 studies found for:    19692680 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MK-3475;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed
2 Recruiting Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer
Condition: Non-small-cell Lung Cancer
Interventions: Drug: Nimotuzumab;   Drug: docetaxel and cisplatin;   Radiation: daily RT (65Gy in 25 fractions) to the chest;   Drug: placebo
3 Recruiting Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
Condition: Advanced Non Small Cell Lung Cancer
4 Recruiting Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
Conditions: Non-small Cell Lung Cancer Metastatic;   EGFR Activating Mutation
Interventions: Drug: Gefitinib;   Drug: gemcitabine;   Drug: carboplatin
5 Not yet recruiting A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Condition: Carcinoma of the Lung.
Interventions: Drug: Binimetinib;   Drug: Pemetrexed;   Drug: Carboplatin
6 Active, not recruiting Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient
Conditions: Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent;   No EGFR Activating Mutation
Interventions: Radiation: 18F-FLT-TEP;   Radiation: 18F-FDG-TEP
7 Unknown  Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC
Condition: Non-small-cell Lung Cancer
Intervention: Drug: Gefitinib
8 Withdrawn A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
Condition: Lung Cancer
Intervention: Drug: BIBW 2992 (Afatinib)
9 Unknown  Tarceva Italian Lung Optimization tRial
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Erlotinib;   Drug: Docetaxel
10 Completed Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: neoadjuvant erlotinib therapy;   Drug: neoadjuvant gemcitabine/carboplatin therapy
11 Completed
Has Results
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Carboplatin;   Drug: Paclitaxel

Indicates status has not been verified in more than two years